---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028753"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:25:35.343201+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Foghorn reports Q3 2022 net loss $25.8M; FDA places FHD-286 AML/MDS trial on full clinical hold

## Summary
- Cash $373.5M as of Sep 30, 2022; runway into 2025.
- FDA full clinical hold on FHD-286 AML/MDS study due to fatal differentiation syndrome; hold to be resolved.
- FHD-286 mUM dose escalation continues; initial data expected H1 2023.
- FHD-609 shows BRD9 degradation in synovial sarcoma biopsies; efficacy/safety data expected 2023.
- New selective CBP degrader program disclosed; Merck collaboration triggered $5M milestone payment.

## SEC filing metadata
- accession: 0001628280-22-028753
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/0001628280-22-028753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/fhtx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028753
- JSON: https://secwatch.observer/filing/0001628280-22-028753.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028753.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported quarter ended September 30, 2022 results: revenue $6.6 million.
  - Period: quarter ended September 30, 2022
  - Revenue: $6.6 million
  - Result: reported results
  source text: Collaboration revenues were $6.6 million for the third quarter of 2022 compared to $0.1 million for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/0001628280-22-028753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.